Detalhe da pesquisa
1.
Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan.
Int J Hematol
; 109(1): 70-78, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30043332
2.
Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan.
Int J Hematol
; 109(2): 241, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30560315
3.
Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan.
Int J Hematol
; 109(3): 336-345, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30604312
4.
Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
Int J Hematol
; 107(1): 123-124, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29149425
5.
Perioperative safety and hemostatic efficacy of Advate® in patients with hemophilia A in a postmarketing surveillance in Japan.
Int J Hematol
; 108(1): 22-29, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29594923
6.
Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
Int J Hematol
; 106(5): 704-710, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28550352